Skip Navigation

Breast cancer - gemcitabine

Gemcitabine for the treatment of metastatic breast cancer

Guidance type:  Technology appraisal
Date issued:  January 2007

We will consult on our review plans for this guidance in January 2010.

Reference:  TA116

Summary

Gemcitabine, which is combined with another medicine called paclitaxel to treat metastatic breast cancer, is only recommended as a possible treatment for people with metastatic breast cancer in situations where two other treatments could also be used as alternatives.

Other treatments that doctors could use in the same situation are a medicine called docetaxel (given on its own) and docetaxel combined with another medicine called capecitabine.

Top

Documents

For healthcare professionals

For patients, carers and the public

Background information

  • None found

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

Top

Search NICE guidance


Advanced guidance search

Related guidance

Click the links below to see guidance on similar topics